Rome wasn’t built in a day… But there is another lesser-known type of keystone, one that plays an equally critical role in supporting the most revolutionary technology the world’s ever seen… artificial intelligence. And without it, the entire AI industry would collapse.

You must read this new presentation from Porter Stansberry.

Detlev Biniszkiewicz net worth and biography

Detlev Biniszkiewicz Biography and Net Worth

Director of iTeos Therapeutics

Dr. Detlev Biniszkiewicz is a serial entrepreneur and an experienced biopharma executive who brings deep knowledge of oncology and immuno-oncology to his role at MPM. Currently, he is President and CEO of two early-stage biotech companies, Rekindle Therapeutics and NextPoint Therapeutics.

Prior to joining MPM, Detlev was the President and CEO of Surface Oncology (NASDAQ: SURF), where he led its growth and transformation through to clinical-stage and its preparation for a public offering. Prior to Surface Oncology, he was Vice President of Strategy in AstraZeneca’s Oncology Unit and was part of the oncology leadership that developed Lynparza® and Tagrisso®, two innovative medicines that help thousands of patients suffering from cancer. His group transformed AstraZeneca’s Oncology pipeline through numerous licensing deals, clinical and academic collaborations, and external research. Detlev has also held multiple roles at Novartis including Global Head of Portfolio, where his group provided oversight of Novartis’ research and early development portfolio. Detlev began his career at the Boston Consulting Group and performed his academic research at the Whitehead Institute for Biomedical Research at the Massachusetts Institute of Technology.

How do I contact Detlev Biniszkiewicz?: The corporate mailing address for Dr. Biniszkiewicz and other iTeos Therapeutics executives is , , . iTeos Therapeutics can also be reached via phone at 339-217-0161 and via email at [email protected]. Learn More on Detlev Biniszkiewicz's contact information.
Has Detlev Biniszkiewicz been buying or selling shares of iTeos Therapeutics?: Detlev Biniszkiewicz has not been actively trading shares of iTeos Therapeutics over the course of the past ninety days. Most recently, Detlev Biniszkiewicz sold 3,500 shares of the business's stock in a transaction on Monday, January 3rd. The shares were sold at an average price of $51.90, for a transaction totalling $181,650.00. Learn More on Detlev Biniszkiewicz's trading history.
Who are iTeos Therapeutics' active insiders?: iTeos Therapeutics' insider roster includes Detlev Biniszkiewicz (Director), Michel Detheux (CEO), Ansbert Gadicke (Major Shareholder), Matthew Gall (CFO), David Hallal (Director), Les Korsh (VP), Joanne Lager (Insider), and Yvonne McGrath (VP). Learn More on iTeos Therapeutics' active insiders.
Are insiders buying or selling shares of iTeos Therapeutics?: During the last year, iTeos Therapeutics insiders bought shares 1 times. They purchased a total of 5,000 shares worth more than $38,650.00. The most recent insider tranaction occured on November, 19th when CFO Matthew Gall bought 5,000 shares worth more than $38,650.00. Insiders at iTeos Therapeutics own 12.5% of the company. Learn More about insider trades at iTeos Therapeutics.
Information on this page was last updated on 11/19/2024.

Detlev Biniszkiewicz Insider Trading History at iTeos Therapeutics

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction	Details
1/3/2022	Sell	3,500	$51.90	$181,650.00

Detlev Biniszkiewicz Buying and Selling Activity at iTeos Therapeutics

iTeos Therapeutics Company Overview

Iteos Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of immuno-oncology therapeutics for patients with cancer. The company's lead antibody product candidate, belrestotug, an antagonist of TIGIT or T-cell immunoreceptor with Ig and ITIM domains, which is in Phase 1b clinical trial, as well as used to engage the Fc gamma receptor, or Fc?R to activate dendritic cells, natural killer cells, and macrophages and to promote antibody-dependent cellular cytotoxicity, or ADCC activity. Its product pipeline also includes inupadenant, a next-generation A2AR antagonists that is in Phase 1/2a clinical trials to overcome the specific adenosine-mediated immunosuppression found in tumor microenvironment; and EOS-984, a small molecule targeting equilibrative nucleoside transporter 1 (ENT1) to inhibit the immunosuppressive activity of adenosine and restore immune cell proliferation is in Phase 1 clinical trials. Iteos Therapeutics, Inc. was founded in 2011 and is headquartered in Watertown, Massachusetts.

Today's Range

Now: $8.31

$8.19

$8.45

50 Day Range

MA: $9.13

$7.85

$10.60

2 Week Range

Now: $8.31

$7.54

$18.75

Volume

110,728 shs

Average Volume

444,258 shs

Market Capitalization

$303.56 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.37

This company will win the AI race

From Porter & Company | Ad